William Blair Issues Optimistic Estimate for VIGL Earnings

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Equities research analysts at William Blair increased their Q2 2025 EPS estimates for Vigil Neuroscience in a report released on Thursday, May 22nd. William Blair analyst M. Minter now expects that the company will post earnings of ($0.50) per share for the quarter, up from their prior forecast of ($0.52). William Blair has a "Hold" rating on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience's Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.07) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($2.03) EPS.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04.

Other equities research analysts also recently issued reports about the stock. Wedbush downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and cut their price target for the company from $13.00 to $8.00 in a report on Thursday, May 22nd. Mizuho downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Jefferies Financial Group cut Vigil Neuroscience to a "hold" rating in a research report on Thursday, May 22nd. Citigroup lowered Vigil Neuroscience to a "market perform" rating in a research note on Thursday, May 22nd. Finally, Stifel Nicolaus lowered Vigil Neuroscience from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $11.00 to $8.00 in a research report on Wednesday. Ten investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Vigil Neuroscience presently has an average rating of "Hold" and an average target price of $10.80.

Vigil Neuroscience Stock Up 0.1%

Shares of VIGL traded up $0.01 during mid-day trading on Monday, reaching $7.89. 78,123 shares of the stock traded hands, compared to its average volume of 1,097,528. The stock has a fifty day simple moving average of $2.67 and a 200 day simple moving average of $2.42. Vigil Neuroscience has a 12-month low of $1.31 and a 12-month high of $7.95. The firm has a market cap of $368.01 million, a price-to-earnings ratio of -3.83 and a beta of 1.90.

Institutional Trading of Vigil Neuroscience

Hedge funds have recently made changes to their positions in the company. abrdn plc raised its stake in Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after purchasing an additional 293,461 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares in the last quarter. Barclays PLC lifted its position in Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares during the period. Blair William & Co. IL bought a new position in shares of Vigil Neuroscience during the fourth quarter valued at $551,000. Finally, 683 Capital Management LLC increased its holdings in shares of Vigil Neuroscience by 14.8% during the fourth quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company's stock valued at $2,380,000 after acquiring an additional 180,420 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.